Literature DB >> 15123038

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.

Marc Feldmann1, Fionula M Brennan, Richard O Williams, James N Woody, Ravinder N Maini.   

Abstract

The development of anti-TNF therapy is a key step forward in rheumatology as it is the first new therapy for based on investigating the molecular mechanisms of this disease. This chapter reviews how this discovery was made.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15123038     DOI： 10.1016/j.berh.2003.09.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN： 1521-6942            Impact factor:   4.098


  24 in total

Review 1.  Analysing the effect of novel therapies on cytokine expression in experimental arthritis.

Authors:  Richard O Williams; Julia J Inglis; Egle Simelyte; Gabriel Criado; Percy F Sumariwalla
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

Review 2.  What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Authors:  W G Dixon; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2007-01-24       Impact factor: 19.103

3.  Alternative for anti-TNF antibodies for arthritis treatment.

Authors:  Joseph Paquet; Christel Henrionnet; Astrid Pinzano; Jean-Baptiste Vincourt; Pierre Gillet; Patrick Netter; Isabelle Chary-Valckenaere; Damien Loeuille; Jacques Pourel; Laurent Grossin
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

4.  Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Authors:  David J Shealy; Ann Cai; Kim Staquet; Audrey Baker; Eilyn R Lacy; Laura Johns; Omid Vafa; George Gunn; Susan Tam; Sarah Sague; Dana Wang; Mike Brigham-Burke; Paul Dalmonte; Eva Emmell; Bill Pikounis; Peter J Bugelski; Honghui Zhou; Bernard J Scallon; Jill Giles-Komar
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

5.  Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor.

Authors:  Jeremy Sokolove; Xiaoyan Zhao; Piyanka E Chandra; William H Robinson
Journal:  Arthritis Rheum       Date:  2011-01

Review 6.  In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome.

Authors:  Chun-Ming Huang; Teruaki Nakatsuji; Yu-Tseung Liu; Yang Shi
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-01       Impact factor: 4.169

7.  High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy.

Authors:  Dongyi He; Fengmin Bai; Shu Zhang; Ting Jiang; Jie Shen; Qi Zhu; Tao Yue; Lingyun Shao; Yan Gao; Yun Feng; Xinhua Weng; Hejian Zou; Ying Zhang; Wenhong Zhang
Journal:  Clin Vaccine Immunol       Date:  2013-04-03

Review 8.  Management of Children with Juvenile Idiopathic Arthritis.

Authors:  Vijay Viswanathan; Kevin J Murray
Journal:  Indian J Pediatr       Date:  2015-12-07       Impact factor: 1.967

9.  Synthesis and biological evaluation of imidazo[1,2-[Formula: see text]]pyridazines as inhibitors of TNF-[Formula: see text] production.

Authors:  Shivaji S Pandit; Mahesh R Kulkarni; Usha Ghosh; Yashwant B Pandit; Nitin P Lad
Journal:  Mol Divers       Date:  2017-12-02       Impact factor: 2.943

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.